NCT05902988 - A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions

Advanced Solid TumorHigh Grade Serous Adenocarcinoma of OvarySquamous Non-small-cell Lung CancerTriple Negative Breast CancerHead and Neck Squamous Cell CarcinomaOvarian CarcinosarcomaUterine CarcinosarcomaUterine Serous CarcinomaEndometrium CancerChromosomal Instability

Interventions

DRUG

VLS-1488

VLS-1488 tablets will be given orally.

Trial Locations (13)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

21224

RECRUITING

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore

45219

RECRUITING

The Christ Hospital, Cincinnati

46256

RECRUITING

Community Health Network, Indianapolis

48109

RECRUITING

University of Michigan, Ann Arbor

49546

ACTIVE_NOT_RECRUITING

START Midwest, Grand Rapids

53226

RECRUITING

Froedtert & the Medical College of Wisconsin, Milwaukee

60201

RECRUITING

Kellogg Cancer Center, Evanston

77030

RECRUITING

M.D. Anderson Cancer Center, Houston

80045

RECRUITING

University of Colorado Cancer Center, Aurora

90033

RECRUITING

University of Southern California, Los Angeles

06511

RECRUITING

Yale Cancer Center, New Haven

02905

RECRUITING

Women & Infants Hospital, Providence

All Listed Sponsors

lead

Volastra Therapeutics, Inc.

INDUSTRY